News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Maplight Therapeutics Has Announced the Successful Completion of the Second Phase 1 Clinical Trial for Their Novel Muscarinic Receptor Agonist, ML-007
Friday, August 25, 2023MapLight Therapeutics a clinicalstage biopharmaceutical company has successfully completed a second Phase clinical trial for its novel compound ML This compound is designed to target MM muscarinic receptor agonists with the aim of addressing brain
Techbio Pioneer Etcembly Introduces Industry's First Generative AI-crafted Bispecific T Cell Engager Exhibiting Picomolar Affinity
Thursday, August 24, 2023Etcembly a British techbio startup has emerged from stealth mode to reshape the landscape of immunotherapy Utilizing a pioneering pipeline of T cell receptor TCR therapeutics crafted through generative AI the company represents a remarkable stride fo...
Ventus Therapeutics Launches Phase 1 Clinical Trial for VENT-02: a New Orally Administered NLRP3 Inhibitor with Enhanced Brain Penetration
Wednesday, August 23, 2023Ventus Therapeutics has commenced a Phase clinical trial for VENT a groundbreaking oral NLRP inhibitor engineered to address neuroinflammatory diseases Marcelo Bigal MD PhD the CEO of the company expressed enthusiasm about reaching this pivotal junc...
Paradigm Therapeutics Acquires Advanced Late-stage "Breakthrough Therapy" for Treating All Subtypes of Epidermolysis Bullosa (EB)
Wednesday, August 23, 2023Paradigm Therapeutics Inc a prominent biopharmaceutical firm has successfully concluded the acquisition of the global rights to SD from Amicus Therapeutics SD represents a topical remedy designed to address all subtypes of Epidermolysis Bullosa EB
European Medicines Agency Approves Orphan Disease Application for Cellspan Esophageal Implant
Tuesday, August 22, 2023Harvard Apparatus Regenerative Technology Inc OTCQB HRGN a clinicalstage biotechnology firm specializing in organ regeneration to address severe diseases has disclosed the European Medicines Agencys EMA endorsement of an Orphan Disease Application fo...
Mysthera Therapeutics Launches Initiative to Develop Innovative Therapies for Autoimmune Diseases
Tuesday, August 22, 2023Mysthera Therapeutics AG has just launched with a starting investment of million from its initial investor Forty Ventures The companys main focus is on developing novel oral treatments for complex autoimmune disorders
Willow and a Leading Innovator in Biopharmaceuticals Collaborate on Developing Eco-friendly Intermediates and Active Pharmaceutical Ingredients
Monday, August 21, 2023Willow Biosciences Inc has recently entered into a collaboration with a biopharmaceutical company listed on Nasdaq The aim of this partnership is to develop more sustainable manufacturing processes for important intermediates and active pharmaceutica...
IND Application Approval for Development Candidate GSK101 (IDE705) Targeting Pol Theta Helicase
Monday, August 21, 2023IDEAYA Biosciences Obtains IDEAYA Biosciences Inc NASDAQ IDYA a company specializing in precision medicine oncology and dedicated to the research and development of targeted therapeutics has announced the approval of an Investigational New Drug IND a...
BITT Granted FDA Acceptance of IND Application for TNFR2 Antibody
Saturday, August 19, 2023Boston Immune Technologies and Therapeutics Inc BITT a clinicalstage biotechnology firm specializing in novel treatments has received the green light from the Food and Drug Administration
Pieris Pharmaceuticals Achieves Milestone as Boston Pharmaceuticals Initiates Phase 1/2 Study of BOS-342, a Promising 4-1BB/GPC3 Immuno-oncology Bispecific
Friday, August 18, 2023Pieris Pharmaceuticals Inc recently achieved an undisclosed milestone payment from Boston Pharmaceuticals a result of successfully dosing the first patient in a phase study sponsored by Boston Pharmaceuticals
